Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion

B Cell Lymphoma Clinical Trial

Official title:

Addition of Nivolumab to Standard of Care With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05385263
• Other study ID #: 0804-21
• Status: Recruiting
• Phase: Phase 2
• Start date: May 11, 2022
• Est. completion date: October 2024

Study information

• Verified date: April 2022
• Source: Tel-Aviv Sourasky Medical Center
• Contact: Ron Ram, Prof
• Phone: 972-3-6947830
• Email: ronr[@]tlvmc.gov.il
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Progression of DLBCL is the major obstacle for the success of chimeric antigen receptor-T cell (CAR-T) with approximately 60% of the patients relapsing in the first year, and 40% within 3 months, after infusion. While patient with DLBCL in Partial Response/Complete Response at lymphodepletion have a 1-year Progression Free Survival (PFS) of 60-80%, those with Stable Disease/Progressive Disease at time of lymphodepletion have a dismal PFS of 20-30%. Trials showed that better expansion of CAR-T cells, even in patients with a progressive disease, may overcome this grave prognosis and may result in better PFS

Description:

Factors that may introduce resistance to CAR-T. in addition to the bulk of disease, include also expression of check point molecules that eventually interfere with the CAR-T action. The investigator, have recently shown (EBMT 2022, # LWP-03) a real-life data, that day +7 CAR-T concentration in patients with stable or progressive disease (SD/PD) at lymphodepletion segregates patients to those with high CAR-T blood concentrations that achieve a high CR/PR rate after CAR-T infusion ,those with 20-100 CAR-T cells/microL that achieve a lower CR/PR rate after CAR-T infusion, and those with <20 cells/microL that achieve the lowest CR/PR rate after infusion. Thus, the extent of CAR-T cell expansion on day 7 after treatment is a prognostic marker predicting response to treatment in this patient group. Considering all these - patients with SD/PD at time of lymphodepletion, and specifically those with lower CAR-T blood concentrations on day +7 are at a very high risk for early disease progression after CAR-T infusion and, as such, there is an urgent unmet medical need to improve their outcomes. Addition of anti PD-1 to patients with low expansion of CAR-T cells may overcome the inhibitory effect of PD-1 expression and may result in a better function of the CAR-T and eventually tumor suppression. Nivolumab is a human monoclonal antibody targeting (programmed death-1 ) PD-1, a negative regulatory molecule expressed by activated T and B lymphocytes. Anti PD-1 treatment has been administered as a single dose or repeated administration in different time points during CAR-T cell therapy. These studies showed that this treatment is safe, well tolerated and does not result in increased CAR-T associated toxicities, mainly cytokine release syndrome(CRS) and immune effector cell associated neurotoxicity(ICANS). The optimal time window to administer these agents for achieving safety and efficacy is not determined.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: October 2024
• Est. primary completion date: April 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Participant must be at least 18 years of age inclusive, at the time of signing the informed consent.

2. DLBCL treated with CAR-T targeting CD19 (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel)

3. PD/SD by PET-CT on the day of lymphodepletion

4. Capable of giving signed informed consent

5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

6. No active CRS or ICANS at time of nivolumab administration

Exclusion Criteria:

1. Hypersensitivity to checkpoints inhibitors

2. CRS grade 3 and above or ICANS any grade on days 0-5 following CAR-T

3. AST (Aspartate transaminase) or ALT (Alanine transaminase) over 3 times the upper limit of normal (ULN) or total bilirubin over 3 times ULN

4. Serum creatinine over 1.5 times ULN or over 1.5 times baseline

5. History of or active autoimmune disease

6. Uncontrolled seizure activity and/or clinically evident progressive encephalopathy

7. Active diarrhea (more than 4 bowel movements per day)

8. Clinically significant uncontrolled illness

9. Active infection requiring antibiotics

10. Known history of immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection

11. Other active malignancy

12. Females only: Pregnant or breastfeeding

Related Conditions & MeSH terms

• B Cell Lymphoma

Intervention

Drug:
• Nivolumab Injection [Opdivo]
Nivolumab ( 3mg/kg IV) on day +5. If CAR-T expansion<100 cells/microL on day +7 one additional dose of nivolumab (3mg/kg IV) will be given on day +19

Locations

Country	Name	City	State
Israel	Tel-Aviv Sourasky Medicak center / BMT Unit	Tel-Aviv

Sponsors (1)

Lead Sponsor	Collaborator
Tel-Aviv Sourasky Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall response at 1 months after CAR-T infusion	Complete or partial remission rate assessed by PET-CT (Positron Emission Tomography ) at 1 month after combination therapy with nivolumab and CAR-T.	One month post CAR-T infusion
Secondary	Overall survival at 1 year after CAR-T infusion and nivolumab	To assess survival of patients at 1 year after infusion of CAR-T and addition of nivolumab.	One year post CAR-T infusion
Secondary	Duration of response	Assess duration of disease response after CAR-T infusion	One year post CAR-T infusion
Secondary	Cytokine release syndrome	Assesment of cytokine release syndrome according to the American Society for Transplantation and Cellular Therapy (ASTCT) grading system (grade 0-4, 4 being the worse) (TCT. 2019 Apr; 25(4);625-638)	One year post CAR-T infusion
Secondary	Neurotoxicity	Assesment of neurotoxicity according to the American Society for Transplantation and Cellular Therapy (ASTCT) grading system (grade 0-4, 4 being the worse) (TCT. 2019 Apr; 25(4);625-638)	One year post CAR-T infusion
Secondary	Hemophagocytic lymphohistiocytosis (HLH)	Assesment of HLH according to the Common Terminology Criteria for Adverse Events CTCAE (version 5.0) (grade 3-5, 5 being the worse)	One year post CAR-T infusion